The 2026 European Association for the Study of Diabetes (“EASD”) annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster their positions in the booming weight-loss drug market.
Lilly presented full Phase 3 data for its triple-G drug retatrutide, showing that 34.9% of patients on the highest dose lost at least 25% of their body weight, alongside a new combination drug, EloraTZP, that delivered up to 23.3% weight loss in patients with obesity and type 2 diabetes. Novo countered this with real-world data suggesting that Ozempic is associated with a 6% lower risk of major cardiovascular events compared with Lilly’s Mounjaro.
This flurry of competition underscores a critical reality for investors: the rising tide of clinical validation is lifting the entire GLP-1 market.
For those seeking exposure to the weight-loss drug market without getting exposed to single-stock risk, healthcare exchange-traded funds (ETFs), particularly those focused on GLP-1, offer a strategic gateway.
Before identifying these ETFs, it is crucial to understand where the obesity and diabetes care market is heading and the roles Lilly and Novo play in shaping it, creating opportunities across the broader healthcare investment landscape.
GLP-1 Market Trends: LLY, NVO & Beyond
Eli Lilly and Novo Nordisk stand at the center of the diabetes and weight-loss drug market, with both companies racing to capture more shares of the global market for anti-obesity medications, projected to exceed $100 billion by 2030.
The competitive intensity is rising. Eli Lilly's triple-agonist retatrutide has drawn considerable attention for its potential best-in-class efficacy, while Novo Nordisk continues to defend its first-mover advantage in the injectable GLP-1 space through its oral Wegovy launch and pipeline expansion.
Beyond these two leaders, several other prominent pharmaceutical and biotech companies are actively shaping the competitive landscape. Pfizer PFE has re-entered the obesity race with its own oral GLP-1 candidate. To bolster its position in the anti-obesity drug market, it completed its massive $10 billion acquisition of Metsera last year.
Amgen AMGN is advancing MariTide, a long-acting weight-loss injectable with a differentiated mechanism that could offer less frequent dosing.
Regeneron Pharmaceuticals REGN is exploring combination approaches targeting muscle preservation alongside fat loss, addressing a key concern for patients and physicians. The company in-licensed a dual GLP-1/GIP receptor agonist (similar to the mechanism used in tirzepatide) in 2025 to offer its own monotherapy solution for weight loss.
What Lies Ahead for the Weight-Loss Market?
The interconnection between obesity and type 2 diabetes is the biological foundation driving the weight-loss market’s expansion. Currently, more than 27% of adults globally are eligible for GLP-1 receptor agonists for weight management, based on pooled data from 99 countries, per a study conducted by Researchers from Mass General Brigham, Washington University School of Medicine in St. Louis, and Emory University’s Rollins School of Public Health (published in January 2026). This study's authors noted that overall eligibility is driven by the steadily increasing prevalence of obesity globally.
This surely reflects the growing addressable population for GLP-1 medication. The entry of oral formulations has further accelerated adoption by removing the needle barrier, with telehealth providers reporting that patients are choosing pills over injections “by a huge factor.”
As a result, pharma and biotech stocks exposed to the GLP-1 market should continue to rally in the days ahead.
Healthcare ETFs to Win
Against the current backdrop, a diversified ETF strategy should allow investors to capture the sector’s growth while mitigating exposure to any single drug’s clinical or competitive setback, taking into account the scientific complexity, regulatory hurdles and commercial execution risk inherent in this space. Thus, investors eager to gain exposure to the GLP-1 market may consider adding the following ETFs to their portfolios that are poised to gain from the expanding GLP-1 market:
Roundhill GLP-1 & Weight Loss ETF OZEM
This fund, with net assets worth $57.8 million, offers exposure to 25 companies involved in weight-loss drug making. LLY holds the first spot in this fund, with 12.67% weightage, while NOVO holds the second position with 11.07% weightage.
PFE holds the third spot in this fund, with 11.48% weightage, while AMGN holds the ninth position with 4.36% weightage. OZEM charges 59 basis points in fees.
Tema Heart & Health ETF HRTS
This fund, with net assets worth $54.2 million, offers exposure to 46 companies advancing prevention and treatment across chronic conditions, including heart disease, diabetes and obesity. LLY holds the first spot in this fund, with 11.44% weightage, while NOVO holds the fifth position with 4.16% weightage.
HRTS charges 75 basis points (bps) in fees.
Amplify Weight Loss Drug & Treatment ETF THNR
This fund, with net assets worth $5.8 million, offers exposure to 20 global companies expected to economically benefit from weight loss drug development. LLY holds the first spot in this fund, with 10.07% weightage, while NOVO holds the second position with 8.42% weightage.
AMGN holds the fourth spot in this fund, with 5.75% weightage, while PFE holds the fifth position with 5.38% weightage. REGN holds the eighth spot with 4.64% weightage. THNR charges 59 in fees.
Boost Your Portfolio with Our Top ETF Insights
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Tema Heart & Health ETF (HRTS): ETF Research Reports
Amplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports
Roundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports
This article originally published on Zacks Investment Research (zacks.com).